Structure-activity relationships of urotensin II and URP

Peptides

Volumn 29, Issue 5, 2008, Pages 658-673

  Leprince, Jérôme ^a,b,c   Chatenet, David ^a,b,c   Dubessy, Christophe ^a,b,c   Fournier, Alain ^b,d   Pfeiffer, Bruno ^e   Scalbert, Elizabeth ^e   Renard, Pierre ^e   Pacaud, Pierre ^f   Oulyadi, Hassan ^c   Ségalas Milazzo, Isabelle ^c   Guilhaudis, Laure ^c   Davoust, Daniel ^c   Tonon, Marie Christine ^a,b,c   Vaudry, Hubert ^a,b,c  

^a INSERM   (France)

^b International Associated Laboratory Samuel de Champlain   (France)

^c UNIVERSITÉ DE ROUEN   (France)

^d INRS INSTITUT ARMAND FRAPPIER   (Canada)

^e INSTITUT DE RECHERCHES SERVIER   (France)

^f UNIVERSITÉ DE NANTES   (France)

Author keywords

Structure activity relationship; Urotensin II; Urotensin II related peptide

Indexed keywords

ALANINE; ALPHA AMINO ACID; AMINO ACID; CYSTEINE; DEXTRO AMINO ACID; DISULFIDE; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 14; LIGAND; LYSINE; PHENYLALANINE; PROTEIN DERIVATIVE; TRYPTOPHAN; TYROSINE; UNCLASSIFIED DRUG; URANTIDE; UROTENSIN II; UROTENSIN II RELATED PEPTIDE;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ATHEROSCLEROSIS; BEHAVIOR; BIOASSAY; BIOLOGICAL ACTIVITY; CARBOXY TERMINAL SEQUENCE; CARDIOVASCULAR RESPONSE; CONFORMATIONAL TRANSITION; DIABETES MELLITUS; ENDOCRINE GLAND; HEART FAILURE; KIDNEY; KIDNEY DYSFUNCTION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN STABILITY; PROTEIN STRUCTURE; RESPIRATORY SYSTEM; REVIEW; SMOOTH MUSCLE; STRUCTURE ACTIVITY RELATION;

ALANINE; AMINO ACID SEQUENCE; ANIMALS; CYSTEINE; DISULFIDES; HUMANS; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; PEPTIDE FRAGMENTS; PEPTIDE HORMONES; PROTEIN CONFORMATION; SEQUENCE ALIGNMENT; STRUCTURE-ACTIVITY RELATIONSHIP; TYROSINE; UROTENSINS;

EID: 42049091623     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2007.08.014     Document Type: Review

References (105)

1. Ames R.S., Sarau H.M., Chambers J.K., Willette R.N., Aiyar N.V., Romanic A.M., et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401 (1999) 282-286
2. Behm D.J., Ao Z., Camarda V., Aiyar N.V., Johns D.G., and Douglas S.A. Inhibitory effects of putative peptidic urotensin-II receptor antagonists on urotensin-II-induced contraction of cat isolated respiratory smooth muscle. Eur J Pharmacol 516 (2005) 276-281
3. Behm D.J., Harrison S.M., Ao Z., Maniscalco K., Pickering S.J., Grau E.V., et al. Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice. Br J Pharmacol 139 (2003) 464-472
4. Behm D.J., Stankus G., Doe C.P., Willette R.N., Sarau H.M., Foley J.J., et al. The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems. Br J Pharmacol 148 (2006) 173-190
5. Bhaskaram R., Arunkumar A.I., and Yu C. NMR and dynamical simulated annealing studies on the solution conformation of urotensin II. Biochem Biophys Acta 1199 (1994) 115-122
6. Bottrill F.E., Douglas S.A., Hiley C.R., and White R. Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br J Pharmacol 130 (2000) 1865-1870
7. Boucard A.A., Sauve S.S., Guillemette G., Escher E., and Leduc R. Photo-labeling the rat urotensin II/GPR14 receptor identifies a ligandbinding site in the fourth transmembrane domain. Biochem J 370 (2003) 829-838
8. Bousette N., Patel L., Douglas S.A., Ohlstein E.H., and Giaid A. Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis 176 (2004) 117-123
9. Brkovic A., Hattenberger A., Kostenis E., Klabunde T., Flohr S., Kurz M., et al. Functional and binding characterizations of urotensin II-related peptides in human and rat urotensin II-receptor assay. J Pharmacol Exp Ther 306 (2003) 1200-1209
10. Camarda V., Guerrini R., Kostenis E., Rizzi A., Calo G., Hattenberger A., et al. A new ligand for the urotensin II receptor. Br J Pharmacol 137 (2002) 311-314
11. Camarda V., Song W., Marzola E., Spagnol M., Guerrini R., Salvadori S., et al. Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors. Eur J Pharmacol 498 (2004) 83-86
12. Camarda V., Spagnol M., Song W., Vergura R., Roth A.L., Thompson J.P., et al. In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen5, DTrp7, Dab8]urotensin II(4-11) (UFP-803). Br J Pharmacol 147 (2006) 92-100
13. Carotenuto A., Grieco P., Campiglia P., Novellino E., and Rovero P. Unraveling the active conformation of urotensin II. J Med Chem 47 (2004) 1652-1661
14. Castel H., Diallo M., Chatenet D., Leprince J., Desrues L., Schouft M.T., et al. Biochemical and functional characterization of high-affinity urotensin II receptors in rat cortical astrocytes. J Neurochem 99 (2006) 582-595
15. Chartrel N., Conlon J.M., Collin F., Braun B., Waugh D., Vallarino M., et al. Urotensin II in the central nervous system of the frog Rana ridibunda: immunohistochemical localization and biochemical characterization. J Comp Neurol 364 (1996) 324-339
16. Chartrel N., Leprince J., Dujardin C., Chatenet D., Tollemer H., Baroncini M., et al. Biochemical characterization and immunohistochemical localization of urotensin II in the human brainstem and spinal cord. J Neurochem 91 (2004) 110-118
17. Chatenet D., Dubessy C., Boularan C., Scalbert E., Pfeiffer B., Renard P., et al. Structure-activity relationships of a novel series of urotensin II analogs: identification of a urotensin II antagonist. J Med Chem 49 (2006) 7234-7238
18. Chatenet D., Dubessy C., Leprince J., Boularan C., Carlier L., Ségalas-Milazzo I., et al. Structure-activity relationships and structural conformation of a novel urotensin II-related peptide. Peptides 25 (2004) 1819-1830
19. Clark S.D., Nothacker H.P., Wang Z., Saito Y., Leslie F.M., and Civelli O. The urotensin II receptor is expressed in the cholinergic mesopontine tegmentum of the rat. Brain Res 923 (2001) 120-127
20. Clozel M., Binkert C., Birker-Robaczewska M., Boukhadra C., Ding S.S., Fischli W., et al. Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin system. J Pharmacol Exp Ther 311 (2004) 204-212
21. Conlon J.M., Arnold-Reed D., and Balment R.J. Post-translational processing of prepro-urotensin II. FEBS Lett 266 (1990) 37-40
22. Conlon J.M., O'Harte F., Smith D.D., Balment R.J., and Hazon N. Purification and characterization of urotensin II and parvalbumin from an elasmobranch fish, Scyliorhinus canicula (common dogfish). Neuroendocrinology 55 (1992) 230-235
23. Conlon J.M., O'Harte F., Smith D.D., Tonon M.C., and Vaudry H. Isolation and primary structure of urotensin II from the brain of a tetrapod, the frog Rana ridibunda. Biochem Biophys Res Commun 188 (1992) 578-583
24. Conlon J.M., Tostivint H., and Vaudry H. Somatostatin- and urotensin II-related peptides: molecular diversity and evolutionary perspectives. Regul Pept 69 (1997) 95-103
25. Coulouarn Y., Fernex C., Jégou S., Henderson C.E., Vaudry H., and Lihrmann I. Specific expression of the urotensin II gene in sacral motoneurons of developing rat spinal cord. Mech Dev 101 (2001) 187-190
26. Coulouarn Y., Jégou S., Tostivint H., Vaudry H., and Lihrmann I. Cloning, sequence analysis and tissue distribution of the mouse and rat urotensin II precursors. FEBS Lett 457 (1999) 28-32
27. Coulouarn Y., Lihrmann I., Jégou S., Anouar Y., Tostivint H., Beauvillain J.C., et al. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc Natl Acad Sci USA 95 (1998) 15803-15808
28. Coy D.H., Rossowski W.J., Cheng B.L., and Taylor J.E. Structural requirements at the N-terminus of urotensin II octapeptides. Peptides 23 (2002) 2259-2264
29. Do Rego J.C., Chatenet D., Orta M.H., Naudin B., Le Cudennec C., Leprince J., et al. Behavioral effects of urotensin II centrally administered in mice. Neuropharmacology 183 (2005) 103-117
30. Do Rego JC, Vaudry H, Costentin J. Central behavioral actions of urotensin II. Peptides, submitted for publication.
31. Douglas S.A., and Ohlstein E.H. Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc Med 10 (2000) 229-237
32. Egginger J.G., Camus A., and Calas A. Urotensin-II expression in the mouse spinal cord. J Chem Neuroanat 31 (2006) 146-154
33. Eipper B.A., Stoffers D.A., and Mains R.E. The biosynthesis of neuropeptides: peptide alpha-amidation. Annu Rev Neurosci 15 (1992) 57-85
34. Elshourbagy N.A., Douglas S.A., Shabon U., Harrison S., Duddy G., Sechler J.L., et al. Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein coupled receptors from the mouse and monkey. Br J Pharmacol 136 (2002) 9-22
35. Fauchère J.L., and Thurieau C. Evaluation of the stability of peptides and pseudopeptides as a tool in peptide drug design. Adv Drug Res 23 (1992) 127-158
36. Fauchère J.L. Elements for the rational design of peptide drugs. Adv Drug Res 15 (1986) 29-69
37. Flohr S., Kurz M., Kostenis E., Brkovich A., Fournier A., and Klabunde T. Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. J Med Chem 45 (2002) 1799-1805
38. Gartlon J., Parker F., Harrison D.C., Douglas S.A., Ashmeade T.E., Riley G.J., et al. Central effects of urotensin-II following ICV administration in rats. Psychopharmacology 155 (2001) 426-433
39. Gibson A., Bern H.A., Ginsburg M., and Botting J.H. Neuropeptide-induced contraction and relaxation of the mouse anococcygeus muscle. Proc Natl Acad Sci USA 81 (1984) 625-629
40. Grant M., Patel R.C., and Kumar U. The role of subtype-specific ligand binding and the C-tail domain in dimer formation of human somatostatin receptors. J Biol Chem 279 (2004) 38636-38643
41. Grieco P., Carotenuto A., Campiglia P., Marinelli L., Lama T., Patacchini R., et al. Urotensin-II receptor ligands. From agonist to antagonist activity. J Med Chem 48 (2005) 7290-7297
42. Grieco P., Carotenuto A., Campiglia P., Zampelli E., Patacchini R., Maggi C.A., et al. A new, potent urotensin II receptor peptide agonist containing a Pen residue at the disulfide bridge. J Med Chem 45 (2002) 4391-4394
43. Grieco P., Carotenuto A., Patacchini R., Maggi C.A., Novellino E., and Rovero P. Design, synthesis, conformational analysis, and biological studies of urotensin-II lactam analogues. Bioorg Med Chem 10 (2002) 3731-3739
44. Guerrini R., Camarda V., Marzola E., Arduin M., Calo G., Spagnol M., et al. Structure-activity relationship study on human urotensin II. J Peptide Sci 11 (2005) 85-90
45. Guttmann S.T., and Boissonnas R.A. Influence of the structure of the N-terminal extremity of alpha-MSH on the melanophore stimulating activity of this hormone. Experientia 17 (1961) 265-267
46. Hameury E, Lihrmann I, Vaudry H, Tostivint H. Molecular cloning of the cDNA encoding the prepro-urotensin II-related peptide in zebrafish. NCBI protein database 2006; accession number ABF83596.
47. Hay D.W., Luttmann M.A., and Douglas S.A. Human urotensin-II is a potent spasmogen of primate airway smooth muscle. Br J Pharmacol 131 (2000) 10-12
48. Horie S., Yasuda S., Tsurumaki Y., Someya A., Saito T., Okuma Y., et al. Contraction of isolated guinea-pig ileum by urotensin II via activation of ganglionic cholinergic neurons and acetylcholine release. Neuropharmacology 45 (2003) 1019-1027
49. Ichikawa T., Lederis K., and Kobayashi H. Primary structures of multiple forms of urotensin II in the urophysis of the carp Cyprinus carpio. Gen Comp Endocrinol 55 (1984) 133-141
50. Itoh H., Itoh Y., Rivier J., and Lederis K. Contraction of major artery segments of rat by fish neuropeptide urotensin II. Am Phys Soc 252 (1987) R361-R366
51. Jégou S., Cartier D., Dubessy C., Gonzalez B., Chatenet D., Tostivint H., et al. Localization of the urotensin II receptor in the rat central nervous system. J Comp Neurol 495 (2006) 21-36
52. Kinney W.A., Almond H.R., Qi J., Smith C.E., Santulli R.J., de Garavilla L., et al. Structure-function analysis of urotensin II and its use in the construction of a ligand-receptor working model. Angew Chem Int Ed 41 (2002) 2940-2944
53. Labarrère P., Chatenet D., Leprince J., Marionneau C., Loirand G., Tonon M.C., et al. Structure-activity relationships of human urotensin II and related analogues on rat aortic ring contraction. J Enz Inh Med Chem 18 (2003) 77-88
54. Lancien F., Leprince J., Mimassi N., Mabin D., Vaudry H., and Le Mevel J.C. Central effects of native urotensin II on motor activity, ventilatory movements, and heart rate in the trout Oncorhynchus mykiss. Brain Res 1023 (2004) 167-174
55. Langham R.G., Kelly D.J., Gow R.M., Zhang Y., Dowling J.K., Thomson N.M., et al. Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy. Am J Kidney Dis 44 (2004) 826-831
56. Le Mevel J.C., Olson K.R., Conklin D., Waugh D., Smith D.D., Vaudry H., et al. Cardiovascular actions of trout urotensin II in the conscious trout, Oncorhynchus mykiss. Am J Physiol 271 (1996) R1335-R1343
57. Lescot E, Bureau R, Rault S. Non-peptide urotensin-II receptor agonists and antagonists: review and structure-activity relationships. Peptides, in press.
58. Liu Q., Pong S.S., Zeng Z., Zhang Q., Howard A.D., Williams D.L., et al. Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. Biochem Biophys Res Commun 266 (1999) 174-178
59. Lu W., Greenwood M., Dow L., Yuill J., Worthington J., Brierley M.J., et al. Molecular characterization and expression of urotensin II and its receptor in the flounder (Platichthys flesus): a hormone system supporting body fluid homeostasis in euryhaline fish. Endocrinology 147 (2006) 3692-3708
60. Lu W. NCBI protein database 2005; accession number CAI53670.
61. Maguire J.J., Kuc R.E., and Davenport A.P. Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br J Pharmacol 131 (2000) 441-446
62. Marchese A., Heiber M., Nguyen T., Heng H.H.Q., Saldivia V.R., Cheng R., et al. Cloning and chromosomal mapping of three novel genes, GPR9, GPR10, and GPR14, encoding receptors related to interleukin 8, neuropeptide Y, and somatostatin receptors. Genomics 29 (1995) 335-344
63. Marco J., Egido E.M., Hernandez R., and Silvestre R.A. Evidence for endogenous urotensin-II as an inhibitor of insulin secretion, study in the perfused rat pancreas. Peptides 29 (2008) 852-858
64. Matsumoto Y., Abe M., Watanabe T., Adachi Y., Yano T., Takahashi H., et al. Intracerebroventricular administration of urotensin II promotes anxiogenic-like behaviors in rodents. Neurosci Lett 358 (2004) 99-102
65. Matsushita M., Shichiri M., Imai T., Iwashina M., Tanaka H., Takasu N., et al. Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens 19 (2001) 2185-2190
66. McMaster D., Belenky M.A., Polenov A.L., and Lederis K. Isolation and amino acid sequence of urotensin II from the sturgeon Acipenser ruthenus. Gen Comp Endocrinol 87 (1992) 275-285
67. McMaster D., Kobayashi Y., Rivier J., and Lederis K. Characterization of the biologically and antigenically important regions of urotensin II. Proc West Pharmacol Soc 29 (1986) 205-208
68. McMaster D., and Lederis K. Isolation and amino acid sequence of two urotensin II peptides from Catostomus commersoni urophyses. Peptides 4 (1983) 367-373
69. Mori M., Sugo T., Abe M., Shimomura Y., Kurihara M., Kitada C., et al. Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14). Biochem Biophys Res Commun 265 (1999) 123-129
70. Nothacker H.P., Wang Z., McNeill A.M., Saito Y., Merten S., O'Dowd B., et al. Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction. Nat Cell Biol 1 (1999) 383-385
71. Ohsako S., Ishida I., Ichikawa T., and Deguchi T. Cloning and sequence analysis of cDNAs encoding precursors of urotensin II-α and -γ. J Neurosci 6 (1986) 2730-2735
72. Onan D., Hannan R.D., and Thomas W.G. Urotensin II: the old kid in town. Trends Endocrinol Metab 15 (2004) 175-182
73. Patacchini R., Santicioli P., Giuliani S., Grieco P., Novellino E., Rovero P., et al. Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta. Br J Pharmacol 140 (2003) 1155-1158
74. Patel R.C., Lange D.C., and Patel Y.C. Photobleaching fluorescence resonance energy transfer reveals ligand-induced oligomer formation of human somatostatin receptor subtypes. Methods 27 (2002) 340-348
75. Pearson D., Shively J.E., Clark B.R., Geschwind I.I., Barkley M., Nishioka R.S., et al. Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes. Proc Natl Acad Sci USA 77 (1980) 5021-5024
76. Pelletier G., Lihrmann I., Dubessy C., Luu-The V., Vaudry H., and Labrie F. Androgenic down-regulation of urotensin II precursor, urotensin II-related peptide precursor and androgen receptor mRNA in the mouse spinal cord. Neuroscience 132 (2005) 689-696
77. Pelletier G, Lihrmann I, Vaudry H. Role of androgens in the regulation of urotensin II precursor mRNA expression in the rat brainstem and spinal cord. Neuroscience 2002;115:525-32.
78. Perkins T.D.J., Bansal S., and Barlow D.J. Molecular modelling and design of analogues of the peptide hormone urotensin II. Biochem Soc Trans 18 (1990) 918-919
79. Pfeiffer M., Koch T., Schröder H., Klutzny M., Kirscht S., Kreienkamp H.J., et al. Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A). J Biol Chem 276 (2001) 14027-14036
80. Pfeiffer M., Koch T., Schröder H., Laugsch M., Höllt V., and Schulz S. Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization. J Biol Chem 277 (2002) 19762-19772
81. Praissman M., Fara J., Praissman L.A., and Berkowitz J.M. Preparation of an N-acetyl-octapeptide of cholecystokinin. The role of N-acetylation in protecting the octapeptide from degradation by smooth muscle tissues. Biochim Biophys Acta 716 (1982) 240-248
82. Predicted sequence similar to urotensin II transcript. NCBI protein database 2006; accession number XP_582447.
83. Russell F.D. Emerging roles of urotensin II in cardiovascular disease. Pharmacol Ther 103 (2004) 223-243
84. Sauzeau V., Le Mellionnec E., Bertoglio J., Scalbert E., Pacaud P., and Loirand G. Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ Res 88 (2001) 1102-1104
85. Silvestre R.A., Egido E.M., Hernandez R., Leprince J., Chatenet D., Tollemer H., et al. Urotensin-II is present in pancreatic extracts and inhibits insulin release in the perfused rat pancreas. Eur J Endocrinol 151 (2004) 803-809
86. Silvestre R.A., Rodriguez-Gallardo J., Egido E.M., and Marco J. Inhibition of insulin release by urotensin II-a study on the perfused rat pancreas. Horm Metab Res 33 (2001) 379-381
87. Smyth D.G., Massey D.E., Zakarian S., and Finnie M.D.A. Endorphins are stored in biologically active and inactive forms: isolation of alpha-N-acetyl peptides. Nature 279 (1979) 252-254
88. Song W., McDonald J., Camarda V., Calo G., Guerrini R., Marzola E., et al. Cell and tissue responses of a range of urotensin II analogs at cloned and native urotensin II receptors. Evidence for coupling promiscuity. Naunyn Schmiedebergs Arch Pharmacol 373 (2006) 148-157
89. Sugo T., Murakami Y., Shimomura Y., Harada M., Abe M., Ishibashi Y., et al. Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain. Biochem Biophys Res Commun 310 (2003) 860-868
90. Suzuki S., Wenyi Z., Hirai M., Hinokio Y., Suzuki C., Yamada T., et al. Genetic variations at urotensin II and urotensin II receptor genes and risk of type 2 diabetes mellitus in Japanese. Peptides 25 (2004) 1803-1808
91. Tal M., Ammar D.A., Karpuj M., Krizhanovsky V., Naim M., and Thompson D.A. A novel putative neuropeptide receptor expressed in neural tissue; including sensory epithelia. Biochem Biophys Res Commun 209 (1995) 752-759
92. Tostivint H., Joly L., Lihrmann I., Parmentier C., Lebon A., Morisson M., et al. Comparative genomics provides evidence for close evolutionary relationships between the urotensin II and somatostatin gene families. Proc Natl Acad Sci USA 103 (2006) 2237-2242
93. Tostivint H, Parmentier C, Mille M, Piblinger R, Taxi J, Lihrmann I, et al. Molecular cloning of the cDNA encoding prepro-urotensin II alpha in zebrafish. NCBI protein database 2003; accession number CAI53670.
94. Tostivint H, Parmentier C, Mille M, Piblinger R, Taxi J, Lihrmann I, et al. Molecular cloning of the cDNA encoding prepro-urotensin II beta in zebrafish. NCBI protein database 2003; accession number AAP06756.
95. Tostivint H, Vauchelles R, Lihrmann I, Vaudry H. Molecular cloning of the mRNA encoding prepro-urotensin II-related peptide in chicken. NCBI protein database 2006; accession number AAS68514.
96. Totsune K., Takahashi K., Arihara Z., Sone M., Murakami O., Ito S., et al. Elevated plasma level of immunoreactive urotensin II and its increased urinary excretion in patients with type 2 diabetes mellitus: association with progress of diabetic nephropathy. Peptides 25 (2004) 1809-1814
97. Totsune K., Takahashi K., Arihara Z., Sone M., Satoh F., Ito S., et al. Role of urotensin II in patients on dialysis. Lancet 358 (2001) 810-811
98. Tzanidis A., Hannan R.D., Thomas W.G., Onan D., Autelitano D.J., See F., et al. Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res 93 (2003) 246-253
99. Vergura R., Camarda V., Rizzi A., Spagnol M., Guerrini R., Calo G., et al. Urotensin II stimulates plasma extravasation in mice via UT receptor activation. Naunyn Schmiedebergs Arch Pharmacol 370 (2004) 347-352
100. Watanabe T., Pakala R., Katagiri T., and Benedict C.R. Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation 104 (2001) 16-18
101. Watson A.M., Lambert G.W., Smith K.J., and May C.N. Urotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions. Hypertension 42 (2003) 373-379
102. Waugh D., and Conlon J.M. Purification and characterization of urotensin II from the brain of a teleost (trout, Oncorhynchus mykiss) and an elasmobranch (skate, Raja rhina). Gen Comp Endocrinol 92 (1993) 419-427
103. Waugh D., Youson J., Mims S.D., Sower S., and Conlon J.M. Urotensin II from the river lamprey (Lampetra fluviatilis), the sea lamprey (Petromyzon marinus), and the paddlefish (Polyodon spathula). Gen Comp Endocrinol 99 (1995) 323-332
104. Yano K., Hicks J.W., Vaudry H., and Conlon J.M. Cardiovascular actions of frog urotensin II in the frog, Rana catesbeiana. Gen Comp Endocrinol 97 (1995) 103-110
105. Yano K., Vaudry H., and Conlon J.M. Spasmogenic actions of frog urotensin II on the bladder and ileum of the frog, Rana catesbeiana. Gen Comp Endocrinol 96 (1994) 412-419